Real time insider trading transaction history:
- Insiders are prohibited from making short-swing profits by trading their shares within 6 months of the registration or acquiring the shares.
- Shares are not adjusted for stock split.
"Insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise"
- Peter Lynch
What is insider trading>>
- Peter Lynch
What is insider trading>>
Common stock purchase or sale:
| Transaction Date | Reported DateTime | Company | Symbol | Insider Relationship | Shares Traded | Average Price | Total Amount | Shares Owned | Filing |
| 2024-03-15 Sale | 2024-03-19 2:30 pm | Aquestive Therapeutics Inc. | AQST | Schobel Alexander Mark Chief Innovation/Tech Officer | 50,000 | $6 | $300,000 | 984,476 (Direct) | View |
| 2024-03-08 Sale | 2024-03-12 1:45 pm | Aquestive Therapeutics Inc. | AQST | Schobel Alexander Mark Chief Innovation/Tech Officer | 25,000 | $5.1874 | $129,685 | 1,034,476 (Direct) | View |
| 2022-06-08 Purchase | 2022-06-10 5:26 pm | Aquestive Therapeutics Inc. | AQST | Schobel Alexander Mark Chief Innovation/Tech Officer | 45,871 | $0.96 | $44,036 | 928,742 (Direct) | View |
| 2021-02-09 Sale | 2021-02-10 8:17 pm | Aquestive Therapeutics Inc. | AQST | Schobel Alexander Mark Chief Innovation/Tech Officer | 35,000 | $6.75 | $236,250 | 837,000 (Direct) | View |
| 2021-02-08 Sale | 2021-02-09 4:00 pm | Aquestive Therapeutics Inc. | AQST | Schobel Alexander Mark Chief Innovation/Tech Officer | 40,792 | $6.5 | $265,148 | 872,000 (Direct) | View |
Stock options: Exercise, Award, Grant, Conversion
| Transaction Date | Reported DateTime | Exercisable Expiration | Company | Symnbol | Insider Relationship | Shares Traded | Conversion Price | Shares Owned | Filing |
| 2024-03-09 Tax Withholding(A) | 2024-10-02 2:16 pm | N/A N/A | Aquestive Therapeutics Inc. | AQST | Schobel Alexander Mark Chief Innovation/Tech Officer | 9,645 | $4.88 | 980,726 (Direct) | View |
| 2024-03-09 Tax Withholding | 2024-03-12 1:45 pm | N/A N/A | Aquestive Therapeutics Inc. | AQST | Schobel Alexander Mark Chief Innovation/Tech Officer | 5,895 | $4.88 | 1,034,476 (Direct) | View |
| 2024-03-07 Option Award | 2024-03-11 10:36 am | N/A 2034-03-07 | Aquestive Therapeutics Inc. | AQST | Schobel Alexander Mark Chief Innovation/Tech Officer | 123,750 | $0 | 1,106,621 (Direct) | View |
| 2023-08-09 Option Award | 2023-08-09 4:30 pm | N/A 2026-05-05 | Aquestive Therapeutics Inc. | AQST | Schobel Alexander Mark Chief Innovation/Tech Officer | 50,000 | $0 | 50,000 (Direct) | View |
| 2023-05-05 Option Award | 2023-05-05 4:00 pm | N/A 2026-05-05 | Aquestive Therapeutics Inc. | AQST | Schobel Alexander Mark Chief Innovation/Tech Officer | 50,000 | $0 | 50,000 (Direct) | View |
| 2023-03-09 Option Award | 2023-03-09 3:07 pm | N/A N/A | Aquestive Therapeutics Inc. | AQST | Schobel Alexander Mark Chief Innovation/Tech Officer | 100,000 | $0 | 982,871 (Direct) | View |
| 2022-11-04 Option Award | 2022-11-08 10:22 am | N/A 2032-11-04 | Aquestive Therapeutics Inc. | AQST | Schobel Alexander Mark Chief Innovation/Tech Officer | 40,000 | $0 | 40,000 (Direct) | View |
| 2022-03-10 Option Award | 2022-03-14 11:25 am | N/A 2032-03-10 | Aquestive Therapeutics Inc. | AQST | Schobel Alexander Mark Chief Innovation/Tech Officer | 75,000 | $0 | 75,000 (Direct) | View |
| 2021-03-11 Option Award | 2021-03-15 5:10 pm | N/A 2031-03-11 | Aquestive Therapeutics Inc. | AQST | Schobel Alexander Mark Chief Innovation/Tech Officer | 70,000 | $0 | 70,000 (Direct) | View |